Clinical Trials in Mental Health

Clinical trials in mental health are enormously expensive, complex,

time consuming, labour intensive and logistically challenging.

 

Unfortunately, many fail as it can be difficult to overcome

placebo-responses.

 

Outsourcing studies can also contribute to failure, and many pharmaceutical companies have stopped doing mental

health drug development for this reason.

 

However, PsiloTec has leveraged decades of expertise in this

area to design studies that minimize these risks.

pexels-karolina-grabowska-4021808.jpg

There is already decades of available scientific data that supports the potential

effectiveness of psilocybin and other psychedelics in treating

various mental health conditions.

To date, three psychedelic development programs have secured

Breakthrough Therapy Designation (BTD) from the

U.S. Food and Drug Administration, significantly shortening

the projected timelines for drug development,

regulatory review and the path to market.

 

The firms that succeed in this burgeoning market must have

well-funded clinical programs, patentable products,

and a clear, well-defined business development strategy.

 

PsiloTec believes it meets all of these key criteria.

Nurse Talking to Patient